| [1] Maher E A, Furnari F B, Bachoo R M, et al. Malignant glioma: genetics and biology of a grave matter[J]. Genes Dev, 2001, 15(11): 1 311－1 133. [2] Compostella A A, Tosoni V, Blatt, et al. Prognostic factors for anaplastic astrocytomas[J]. J Neurooncol, 2007, 81(3): 295－303. [3] Reifenberger J G, Reifenberger L, Liu, et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p[J]. Am J Pathol, 1994, 145(5): 1 175－1 190. [4] Borodovsky A, Seltzer M J, Riggins G J. Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2[J]. Curr Opin Oncol, 2012, 24(1): 83－9. [5] Brandes A A, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients[J]. J Clin Oncol, 2008, 26(13): 2 192－2 197. [6] Craig A, Cloarec O, Holmes E, et al. Scaling and normalization effects in NMR spectroscopic metabonomic data sets[J]. Anal Chem, 2006, 78(7): 2 262－2 267. [7] Pérez-Enciso M, Tenenhaus M. Prediction of clinical outcome with microarray data: a partial least squares discriminant analysis (PLS-DA) approach[J]. Hum Genet, 2003, 112(5-6): 581－592. [8] Chinnaiyan P, Kensicki E, Bloom G, et al. The metabolomic signature of malignant glioma reflects accelerated anabolic metabolism[J]. Cancer Res, 2012, 72(22): 5 878－5 888. [9] Weljie A M, Bondareva A, Zang P, et al. 1H NMR metabolomics identification of markers of hypoxia-induced metabolic shifts in a breast cancer model system[J]. J Biomol NMR, 2011, 49(3-4): 185－193. [10] Cuperlovic-Culf M, Culf A S, Touaibia M, et al. Targeting the latest hallmark of cancer: another attempt at’magic bullet’drugs targeting cancers’ metabolic phenotype[J]. Future Oncol, 2012, 8(10): 1 315－1 315. [11] Colen C B, Shen Y, Ghoddoussi F, et al. Metabolic targeting of lactate efflux by malignant glioma inhibits invasiveness and induces necrosis: an in vivo study[J]. Neoplasia, 2011, 13(7): 620－632. |
